Posttranslational regulation of liver kinase B1 in human cancer
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.104570 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Lanlin Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Scienc…. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Neoplasms, Protein Processing, Post-Translational. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wake Forest School of Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver kinase B1 (LKB1) is a serine-threonine kinase that participates in multiple cellular and biological processes, including energy metabolism, cell polarity, cell proliferation, cell migration, and many others. LKB1 is initially identified as a germline-mutated causative gene in Peutz-Jeghers syndrome and is commonly regarded as a tumor suppressor due to frequent inactivation in a variety of cancers. LKB1 directly binds and activates its downstream kinases including the AMP-activated protein kinase (AMPK) and AMPK-related kinases by phosphorylation, which has been intensively investigated for the past decades. An increasing number of studies have uncovered the posttranslational modifications (PTMs) of LKB1 and consequent changes in its localization, activity, and interaction with substrates. The alteration in LKB1 function as a consequence of genetic mutations and aberrant upstream signaling regulation leads to tumor development and progression. Here, we review current knowledge about the mechanism of LKB1 in cancer and the contributions of PTMs, such as phosphorylation, ubiquitination, SUMOylation, acetylation, prenylation, and others, to the regulation of LKB1 function, offering new insights into the therapeutic strategies in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Department of Laboratory Me…
- Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Sichuan Cancer Hospital & I…
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Electronic address: hulin@wakehealth.edu.
Förderung
- Wake Forest School of Medicine
- National Natural Science Foundation of China
Zitieren
APA
Hu, L., Liu, M., Tang, B., Li, Q., Pan, B. S., Xu, C., & Lin, H. K. (2023). Posttranslational regulation of liver kinase B1 in human cancer. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.104570
Vancouver
Hu L, Liu M, Tang B, Li Q, Pan BS, Xu C, et al. Posttranslational regulation of liver kinase B1 in human cancer. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.104570
BibTeX
@article{Hu2023,
author = {Hu, Lanlin and Liu, Mingxin and Tang, Bo and Li, Qiang and Pan, Bo-Syong and Xu, Chuan and Lin, Hui-Kuan},
title = {Posttranslational regulation of liver kinase B1 in human cancer},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.104570}
}
EUVIMED